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 45 
Abstract 46 
 47 
Background: Guidelines recommend use of nutritional support during hospital stays of medical 48 
patients at risk for malnutrition. However, the supporting evidence is limited, and there is 49 
growing concern about possible negative effects of nutritional therapy during acute illness on 50 
recovery and clinical outcome. Our aim was thus to test the hypothesis that protocol-guided 51 
individualized nutritional support to reach protein and energy goals reduces the risk of adverse 52 
clinical outcomes in medical inpatients at nutritional risk. 53 
Methods: In a pragmatic, investigator-initiated, open-label, multicenter trial in eight Swiss 54 
hospitals, we randomly assigned 2088 medical inpatients at nutritional risk (Nutritional Risk 55 
Screening [NRS] score ≥3 points) to receive protocol-guided individualized nutritional support to 56 
reach protein and energy goals (intervention group) or standard hospital food (control group). 57 
The composite primary endpoint was adverse clinical outcome defined as all-cause mortality, 58 
intensive care admission, non-elective hospital readmission, major complications and decline in 59 
functional status at 30 days.  60 
Findings: During the hospital stay, energy goals were reached in 79% and protein goals in 76% 61 
of intervention group patients. By 30 days, 232 of 1015 patients (22.9%) in the intervention 62 
group experienced an adverse clinical outcome compared to 272 of 1013 (26.9%) control group 63 
patients (adjusted odds ratio 0.79 [95%CI 0.64 to 0.97], p=0.023). In the intervention group, 64 
there were lower rates of death (73 patients [7.2%] vs. 100 patients [9.9%], adjusted odds ratio 65 
0.65 [95%CI 0.47 to 0.91], p=0.011) and functional decline (35 patients [3.7%] vs. 55 patients 66 
[6.0%], adjusted odds ratio 0.62 [95%CI 0.40 to 0.96], p=0.034).  67 
Interpretation: Among medical inpatients at nutritional risk, use of individualized nutritional 68 
support during the hospital stay increased daily energy and protein intakes, and improved 69 
important clinical outcomes including survival as compared to standard hospital food.  70 
Trial registration: ClinicalTrials.gov number, NCT02517476 71 
Funding: The Swiss National Science Foundation (SNSF) (PP00P3_150531) and the Research 72 
Council of the Kantonsspital Aarau (1410.000.058 and 1410.000.044) provided funding for the 73 
trial. 74 
75 
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Introduction 76 
Anorexia, which is part of the acute physiologic response to acute illness, predisposes patients 77 
during a hospital stay to accumulation of serious energy and protein deficits.1 In combination 78 
with immobilization and a pronounced inflammatory and endocrine stress response, these 79 
nutritional deficits contribute to muscle wasting and progressive deterioration of metabolic and 80 
functional status, particularly in the multimorbid medical inpatient population.2,3 As a result, more 81 
than 30% of medical inpatients are at increased risk for malnutrition, a condition that is strongly 82 
associated with higher mortality and morbidity, functional decline, prolonged hospital stays and 83 
increased health care costs.4-6  84 
Current clinical practice guidelines, including the European Society for Clinical Nutrition and 85 
Metabolism (ESPEN)7 and the American Society for Parenteral and Enteral Nutrition (ASPEN)8, 86 
recommend to consider initiating nutritional support during the hospital stay of medical patients 87 
identified by screening and assessment as at risk of malnutrition. However, these 88 
recommendations are largely based on physiological rationales and observational studies. 89 
Some smaller trials have found that nutritional support led to shorter hospital stays and lower 90 
mortality.9-12 Yet, two recent meta-analyses reported no significant improvements in medical 91 
outcomes associated with nutritional interventions in medical inpatients, despite higher energy 92 
and protein intake of patients receiving nutritional support.13,14 Additionally, nutritional support in 93 
medical inpatients with acute illnesses are currently challenged by results of several recent high 94 
quality critical care trials reporting harmful effects of full replacement feeding strategies.1 These 95 
negative effects may be explained by suppression of autophagy with inadequate clearance of 96 
acute illness-associated cell damage.15 97 
In view of the lack of high-quality data in the medical inpatient setting and possible conflicts 98 
between current recommendations for medical inpatients and critical care trials, we conducted 99 
the Effect of early nutritional support on Frailty, Functional Outcomes and Recovery of 100 
malnourished medical inpatients Trial (EFFORT). We tested the hypothesis that protocol-guided 101 
individualized nutritional support to reach protein and energy goals reduces the risk of adverse 102 
clinical outcomes in medical inpatients at nutritional risk. 103 
104 
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Materials and Methods 105 
Study design, registration and oversight 106 
EFFORT is a pragmatic, investigator-initiated, open-label, non-blinded, non-commercial, 107 
multicenter, randomized-controlled trial, that was undertaken in eight Swiss hospitals. The 108 
rationale for the trial, design details, and eligibility features have been published previously.16  109 
The ethical committee of the Northwestern part of Switzerland (EKNZ; 2014_001) approved the 110 
study protocol in January 2014 and the trial was started with a pilot in April 2014. After funding 111 
for the trial was secured and the pilot showed high feasibility regarding the nutritional 112 
intervention , the trial was registered at ClinicalTrials.gov in August 2015 113 
(https://clinicaltrials.gov/ct2/show/NCT02517476) and patient enrollment was broadened to all 114 
participating centers. There was no change in protocol regarding outcomes and interventional 115 
procedures between the initial IRB protocol and the final trial protocol. 116 
 117 
Sites, Patient Selection and Randomization 118 
The eight participating sites were secondary and tertiary care hospitals in Switzerland, and 119 
included the University Clinic in Aarau, the University Hospital in Bern, the Cantonal hospitals in 120 
Lucerne, Solothurn, St. Gallen, Muensterlingen and Baselland, and the hospital Lachen. All 121 
sites routinely used a validated malnutrition screening tool based on the Nutritional Risk 122 
Screening (NRS, 2002 edition).17,18 NRS includes assessment of the patient’s nutritional status 123 
(based on weight loss, body mass index (BMI) and general condition or food intake) and 124 
disease severity (stress metabolism), and is associated with higher risk for adverse outcomes. 125 
Each part is scored from 0 to 3 points, and patients receive an extra point for age above 70 126 
years.  127 
We enrolled patients at nutritional risk (NRS ≥3 points) with an expected length of hospital stay 128 
>4 days if they were willing to provide informed consent within 48 hours of hospital admission. 129 
We excluded patients initially admitted to intensive care units or surgical units, unable to ingest 130 
oral nutrition, already receiving nutritional support on admission, with a terminal condition (i.e., 131 
end-of-life situation), hospitalized because of anorexia nervosa, acute pancreatitis, acute liver 132 
failure, cystic fibrosis or stem cell transplantation, after gastric bypass surgery, or with 133 
contraindications for nutritional support, and patients previously included in the trial. All patients 134 
or their authorized representatives provided written informed consent. 135 
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Patients were randomly assigned in a 1:1 ratio with variable block size, stratified according to 136 
site and the severity of malnutrition, with the use of an interactive web-response system, to 137 
receive either individualized nutritional support (intervention group) or standard hospital food 138 
(control group).  139 
 140 
Study interventions 141 
In the intervention group, nutritional support was initiated as soon as possible after 142 
randomization within 48 hours after admission. Patients received individualized nutritional 143 
support to reach protein and energy goals according to a previously published consensus 144 
protocol19 in accordance with recent international guidelines.7 Figure 1 shows a summary of the 145 
nutritional intervention. Briefly, individualized nutritional goals – including energy and protein 146 
goals – were defined for each patient upon hospital admission by a trained registered dietician. 147 
Energy requirements were predicted using the weight-adjusted Harris-Benedict equation.20 Daily 148 
protein intake was set at 1.2–1.5 g/kg body weight to adjust for higher protein breakdown during 149 
acute disease,21 with lower targets for patients with acute renal failure (0.8 g per kg of body 150 
weight). To reach these goals, an individual nutritional plan was developed by a trained 151 
registered dietician for each patient. This plan was initially based on oral nutrition provided by 152 
the hospital kitchen (including food adjustment according to patient preferences, food 153 
fortification [e.g., enrichment of hospital food by adding protein powder] and providing patients 154 
with between-meal snacks) and oral nutritional supplements.10,22 A further increase in nutritional 155 
support to enteral tube feeding or parenteral feeding was recommended if at least 75% of 156 
energy and protein targets could not be reached through oral feeding within 5 days. Nutritional 157 
intake was reassessed every 24–48 h throughout the hospital stay by a trained registered 158 
dietician based on daily food records for each patient. Upon hospital discharge, patients 159 
received dietary counseling and, if indicated, a prescription for oral nutritional supplements in 160 
the outpatient setting.  161 
Control group patients received standard hospital food according to their ability and desire to 162 
eat, with no nutritional consultation and no recommendation for additional nutritional support.  163 
 164 
 165 
 166 
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Outcome measures 167 
The composite primary endpoint was defined as adverse clinical outcome and included all-168 
cause mortality, admission to the intensive care unit from the medical ward, non-elective 169 
hospital readmission after discharge, and major complications including adjudicated nosocomial 170 
infection, respiratory failure, a major cardiovascular event (i.e., stroke, intracranial bleeding, 171 
cardiac arrest, myocardial infarction) or pulmonary embolism, acute renal failure, gastro-172 
intestinal events (including hemorrhage, intestinal perforation, acute pancreatitis) or a decline in 173 
functional status of 10% or more from admission to day 30 measured by the Barthel’s index 174 
(scores range from 0 to 100, with higher scores indicating better functional status).23 Detailed 175 
definitions for each component of the primary endpoint are summarized in the supplementary 176 
material. 177 
The main secondary endpoints were each single component of the primary endpoint, daily 178 
protein and energy intakes based on food records for each meal, and total length of hospital 179 
stay. Additional assessment at day 30 included the European Quality of Life 5 Dimensions index 180 
(German Version, EQ-5D index values range from 0 to 1, with higher scores indicating better 181 
quality of life), including the visual-analogue scale (EQ-5D VAS) (scores range from 0 to 100, 182 
with higher scores indicating better health status). Safety endpoints included side effects from 183 
nutritional therapy, defined as gastrointestinal side effects, complications due to tube feeding or 184 
central venous catheter for parenteral nutrition, liver or gallbladder dysfunction, hyperglycemia, 185 
and refeeding syndrome.24  186 
We obtained outcome data through chart review by site research staff and trained registered 187 
dieticians, and phone calls at day 30 by study nurses blinded to group assignment. Mortality of 188 
patients during follow-up was verified by family members or the patient`s family physician. 189 
 190 
Statistical analysis 191 
We tested the hypothesis that individualized nutritional support was superior to standard 192 
hospital food in regard to our primary composite endpoint of adverse clinical outcome. Our 193 
primary hypothesis was that early nutritional therapy would reduce adverse clinical outcome and 194 
mortality within a follow up period of 30 days after the index hospitalization. From preliminary 195 
observational data,25 we estimate that 40% of the target patient population would reach the 196 
primary endpoint within 30 days (10% mortality, 5% ICU admission from the hospital ward, 15% 197 
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complications, 10% functional decline with 10% of patients reaching more than 1 endpoint). We 198 
hypothesize that our nutritional intervention will decrease this risk by an absolute number of 6% 199 
(relative decrease of 15%), i.e., from 40% to 34%. Based on these numbers,25 we estimated 200 
that a sample size of 1016 per group (total number 2032) would have a power of at least 80% to 201 
find a reduction in the likelihood of the primary composite endpoint from 0.40 in the control 202 
group to 0.34 in the intervention group (absolute risk reduction of 6%).  203 
We performed all the analyses in the intention-to-treat population, which included all patients 204 
who had undergone randomization unless they withdrew consent. For the primary outcome, we 205 
compared frequencies using a chi-square test. We also fitted a logistic regression model 206 
adjusted for main prognostic factors (Barthel’s index and NRS at baseline) and study center as 207 
predefined in the study protocol. We reported adjusted odds ratios (OR) and corresponding 95% 208 
confidence intervals (CI’s). We used a similar statistical approach for secondary endpoints, with 209 
use of Student’s T test and linear regression models for continuous outcomes. We also used the 210 
Kaplan–Meier method to calculate the probability of the primary outcome and all-cause mortality 211 
within 30 days of randomization. 212 
We conducted predefined subgroup analyses by including interaction terms in the regression 213 
models to test for effect modification by important baseline factors.16 Specifically, we tested for 214 
subgroups by patient age, gender, nutritional risk (NRS), initial BMI, admission diagnosis (i.e., 215 
infection, heart failure, acute kidney injury, gastrointestinal disease, tumor) and comorbidities 216 
(diabetes, chronic kidney disease) as defined in the protocol.  217 
We conducted all analyses with STATA 15.1 (StataCorp. 2015. Stata Statistical Software: 218 
Release 15. College Station, TX, USA: StataCorp LP). There were no interim analyses planned 219 
or conducted during the trial.  220 
Role of funders 221 
The Swiss National Science Foundation (SNSF) (PP00P3_150531) and the Research Council 222 
of the Kantonsspital Aarau (1410.000.058 and 1410.000.044) provided funding for the trial. The 223 
funders had no role in data collection, analysis, interpretation, writing of the manuscript and the 224 
decision to submit. The members of the steering committee (Supplementary Appendix) 225 
designed the trial, collected and analyzed the data, prepared the manuscript, and decided to 226 
submit the manuscript for publication. The members of the steering committee take 227 
responsibility for the accuracy of the data set and adherence to the protocol. There was no 228 
commercial involvement in the trial. 229 
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Results 230 
Patients 231 
From April 2014 to February 2018 we screened 5015 patients and enrolled 2088. With 60 232 
patients requesting withdrawal of consent and no other losses to follow-up, our final analysis 233 
cohort consisted of 2028 patients (Figure 2). 234 
Baseline characteristics were similar between groups (Table 1 and supplemental Table S1). 235 
Patients had a mean age of 72.6 years and a mean body mass index of 24.8 kg/m2. All patients 236 
were at nutritional risk, with 31%, 38% and 31% having 3, 4 and ≥5 points in the NRS, 237 
respectively. The most frequent admission diagnoses were infection (n=613, 30.2%), cancer 238 
(n=374, 18.4%) and cardiovascular disease (n=205, 10.1%). Patients had a high burden of 239 
comorbidities, including malignant disease (n=667, 32.9%), chronic kidney disease (n=641, 240 
31.6%), coronary artery disease (n=566, 27.9%), diabetes (n=428, 21.1%) and congestive heart 241 
failure (n=353, 17.4%). 242 
Protocol compliance and nutritional intake 243 
Protocol adherence during the hospital stay was high and energy goals were reached in 79% 244 
and protein goals in 76% of intervention group patients according to the study protocol. Control 245 
group patients reached energy goals in 54% and protein goals in 55%. Compared to the control 246 
group, patients in the intervention group had significantly higher mean  [SD] daily energy (1211 247 
[±517] vs. 1501 [±596] kcal/day, difference 290 (95%CI 240 to 340) kcal/day) and protein 248 
intakes (47 [±21] vs. 57 [±23] g protein/day, difference 10 (95%CI 8 to 12) g protein/day) during 249 
the hospital stay (Figure 3 and supplemental Figure 1). These numbers correspond to 18.2 250 
[±8.8] vs. 22.2 [±9.6] kcal per kg bodyweight per day, and 0.70 [±0.34] vs 0.84 [±0.35] g protein 251 
per kg bodyweight per day, respectively. In the intervention group, 91% of patients received oral 252 
nutritional supplements in combination with enriched hospital nutrition (supplemental Table 253 
S2). Enteral and parenteral nutrition were used in 8 and 12 patients, respectively. In the control 254 
group, 122 patients (12%) received any kind of nutritional support during the hospital stay. On 255 
hospital discharge, oral nutritional supplements were prescribed in 24.1% of patients in the 256 
intervention group compared to 2.1% of patients in the control group. 257 
 258 
Primary endpoint  259 
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We had complete information on the primary endpoint in all patients at 30 days. An adverse 260 
clinical outcome (primary endpoint) occurred in 232 of 1015 patients (22.9%) in the intervention 261 
group and in 272 of 1013 (26.9%) in the control group (adjusted odds ratio 0.79 [95%CI 0.64 to 262 
0.97], p=0.023) (Table 2). Kaplan Meier estimates also show a significant shorter time to reach 263 
the primary endpoint in the control group (Figure 4).  264 
Regarding the different components of the composite primary endpoint, patients in the 265 
intervention group had a lower risk of all-cause mortality within 30 days (73/1015 [7.2%] vs. 266 
100/1013 [9.9%], adjusted odds ratio 0.65 [95% CI 0.47 to 0.91], p=0.011) and a lower risk of 267 
functional decline at day 30 of ≥ 10% in the Barthel index compared to control patients (35/942 268 
[3.7%] vs. 55/913 [6.0%], adjusted odds ratio 0.62 [95% CI 0.40 to 0.96], p=0.034). There were 269 
no differences in rates of intensive care unit admission, non-elective hospital readmission or 270 
major complications between groups. 271 
 272 
Secondary endpoints  273 
When compared to the control group, there was a significant improvement in the activities of 274 
daily living score at 30 days in the intervention group as measured by the Barthel Index 275 
(adjusted difference 3.26 points [95% CI 0.93 to 5.6], p=0.006) and higher quality of life 276 
measured by the EQ-5D index (adjusted difference 0.13 [95% CI 0.09 to 0.17], p<0.001) and 277 
the EQ-5D VAS (adjusted difference 3.06 points [95% CI 0.53 to 5.59], p=0.018). There was no 278 
difference in length of hospital stay between intervention and control group patients (9.6 days 279 
vs. 9.5 days, adjusted difference -0.21 days [95% CI -0.76 to 0.35] p=0.46).  280 
We found no significant differences in potential side effects from nutritional support including 281 
gastrointestinal side-effects, complications due to enteral feeding and hyperglycemia (Table 2). 282 
 283 
Subgroup analysis 284 
The effect of nutritional support on the risk for the primary endpoint was consistent across 285 
predefined subgroups based on age, gender, baseline nutritional risk stratified by NRS, initial 286 
BMI, diagnosis on hospital admission, or diabetes (p interaction for each subgroup analysis 287 
>0.05). However, we found a more pronounced beneficial effect of nutritional support compared 288 
to control group patients in the population of patients with chronic kidney disease (adjusted OR 289 
0.61 [95% CI 0.44 to 0.86], p interaction = 0.045) (Figure 5). Findings regarding subgroup 290 
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analysis for the outcome 30-day mortality were similar, with a consistent effect across 291 
subgroups except for a more pronounced effect in patients with chronic kidney disease 292 
(supplemental Figure 2). 293 
294 
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Discussion  295 
In this multicenter trial, compared to a control group receiving standard hospital food, 296 
individualized nutritional support increased daily energy and protein intakes and lowered the risk 297 
of adverse clinical outcomes at 30 days (primary outcome) and all-cause mortality with 298 
improvements in functional status and quality of life without an apparent increase in adverse 299 
side effects from the intervention. 300 
Several points of this trial are worth mentioning. First, the findings of our trial validate some 301 
previous smaller trials,9-12 but are in contrast to findings of two meta-analyses, which both 302 
reported lack of statistically significant improvements in clinical outcomes.13,14 Set in a real-world 303 
context and without commercial funding, our large-scale trial with high nutritional protocol 304 
adherence and systematic outcome assessment may resolve the current uncertainty about 305 
benefit of nutritional support in medical inpatients. With a number need to treat of 25 to prevent 306 
one adverse clinical outcome and 37 to prevent one death, the nutritional intervention was 307 
effective at low expenditure. The mortality benefit of nutritional support found in EFFORT was 308 
more pronounced compared to results of a pooled meta-analysis including 22 previous trials 309 
(9.8% vs. 10.3%, NNT 200),13 but in the range of the effect reported in the recent NOURISH trial 310 
(4.8% vs 9.7%, NNT 20).9 Second, to increase external validity, EFFORT was pragmatic and 311 
included a broad and unselected population of consecutive multimorbid medical inpatients with 312 
different acute illnesses and chronic co-morbidities. Several previous trials focused on selected 313 
patient populations.9,13,26 The beneficial effects of nutritional support were robust and similar in 314 
subgroups according to patient age, gender, severity of nutritional risk and underlying disease. 315 
The effects were even more pronounced in patients with chronic kidney disease, a condition 316 
known to predispose patients to protein-energy wasting.27 Third, no specific adverse side effects 317 
of the intervention were noted. This is also true for patients with pre-existing diabetes, a 318 
population that was excluded in previous trials due to concerns of hyperglycemia.9 Currently 319 
there is debate about the benefits and optimal use of nutritional support in medical patients with 320 
acute and severe illness28 with respect to dose and quality of proteins and total energy, route of 321 
delivery, and if or how nutritional support needs to be adjusted for specific medical conditions. 322 
28,29 Importantly, slower recovery and more complications were reported in critical care patients 323 
receiving full-replacement feeding.1,30 There are important differences between our study and 324 
recent critical care trials with regard to patient population, severity of disease, and nutritional 325 
intervention. Due to the milder severity of illness in our population, cells may better metabolize 326 
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and use nutrients more effectively because cells are less insulin resistant and there is lower risk 327 
for autophagy.2,31  328 
Our findings should not be used to support full-replacement feeding in medical inpatients. 329 
Rather our concept of using individualized nutritional support with an aim of reaching at least 330 
75% of nutritional goals has better clinical outcomes compared to not providing nutritional 331 
support. Patients in our trial received nutritional support according to a previously published 332 
feeding protocol with individual definition of each patient’s nutritional goals and individualized 333 
nutritional support to reach those goals.19 The nutritional protocol was based on a 334 
pathophysiological rationale and results of observational and smaller randomized trials. Unlike 335 
other trials investigating the effect of specific nutritional formulas,9 we used a variety of 336 
nutritional support strategies with the support of trained dieticians to reach nutritional goals. Our 337 
trial does thus not provide evidence regarding single nutritional components, but rather proves 338 
that the overall strategy of providing nutritional support to reach protein and energy goals during 339 
the acute phase of illness is beneficial for patients. 340 
EFFORT also has important ethical considerations. Despite strong associations in observational 341 
research between malnutrition and adverse clinical outcome, it remained unclear whether 342 
provision of nutritional support indeed has the potential to reduce the risks associated with 343 
malnutrition, or in contrast has deleterious effects on outcomes as demonstrated in critical care 344 
trials.30 After discussions among national experts in the field (i.e., trial collaborators) and our 345 
ethical review board, we were of the opinion that it was ethically acceptable that patients in the 346 
control group received no additional nutritional treatment. This is also in accordance with a 347 
previous Swiss consensus ethical statement pointing out that “intake of standard food and fluids 348 
is a basic right of any patients”, yet any sort of nutritional therapy must be viewed as a 349 
therapeutic measure and must therefore fulfill all criteria for such including proof of clinical 350 
effectiveness, safety and cost-effectiveness.32 For our patient population, such proofs was still 351 
missing and was thus the main aim of this trial. 352 
We are aware of limitations in our study. First, our trial was pragmatic, and blinding of 353 
participants and personnel was deemed to be impractical. Although the primary outcome at 30 354 
days was objective and its assessment was blinded, some of the outcomes assessed during the 355 
hospital stay may have been vulnerable to observer bias. Second, about 20% of intervention 356 
group patients did not fully reach energy and protein goals despite use of the nutritional protocol 357 
implemented by trained dieticians. Similar to real-life experience, several patient, treatment, and 358 
hospital factors (e.g., delay or refusal to start enteral or parenteral nutrition by the patient, early 359 
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discharge of patients, diagnostic exams interfering with nutritional support) may have prevented 360 
full adherence to the protocol. Still, we expect this bias to be conservative with regards to the 361 
relevant endpoints, and protocol adherence was higher as compared to previous nutritional 362 
trials in the medical inpatient setting.13 Third, nutrition in the control group represented the 363 
reality of standard Swiss hospital food, which may not be unconditionally generalizable to other 364 
health care systems. Forth, we did not yet investigate costs of the intervention, but we have 365 
planned to perform a cost-effectiveness analysis based on the trial data in the future. Finally, we 366 
had a delay in registration as we started the trial with a pilot to assure feasibility of the complex 367 
nutritional intervention and to secure funding for the multicenter rollout. However, there was no 368 
change in trial protocol and we thus used all included patients for the final analysis.  369 
Understanding the optimal use of nutritional support is complex because timing, route of 370 
delivery, and the amount and type of nutrients may all affect patient outcomes. In our trial, we 371 
asked the basic question of whether nutritional support during the hospital stay improves clinical 372 
outcomes of medical patients at nutritional risk compared to standard hospital food. This trial 373 
shows that early use of individualized nutritional support to reach protein and energy goals in 374 
medical inpatients at nutritional risk is effective in increasing energy and protein intakes, and in 375 
lowering the risk of adverse outcomes and mortality within 30 days. Our findings strongly 376 
support the concept of systematically screening medical inpatients on hospital admission 377 
regarding nutritional risk, independent of medical condition, followed by a nutritional assessment 378 
and institution of individualized nutritional support in at-risk patients. 379 
380 
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 487 
TABLES AND FIGURE LEGENDS  488 
 489 
Figure 1. Nutritional algorithm used during the trial according to a previous consensus 490 
conference19 491 
In a first step, all medical patients entering the hospital were assessed for risk of 492 
malnutrition within 24-48 h using the Nutritional Risk screening (NRS 2002).33 In 493 
patients with nutritional risk defined as a NRS of ≥3 points, nutritional goals were 494 
defined. These included energy and protein goals, micronutrient goals and other 495 
disease-specific targets. Energy requirements were predicted using the Harris-Benedict 496 
equation. For under- and overweight patients, the formula has to be adjusted for body 497 
weight to improve its accuracy.20 For all patients, a protein intake of 1.2-1.5 g per kg 498 
bodyweight per day was recommended, except for patients with acute renal failure. For 499 
these patients 0.8 g protein per kg per day were recommended. Also, we recommended 500 
supplementation of all patients with multivitamin/multimineral supplements. 501 
Once goals were set, a nutritional plan to achieve these goals was established. We 502 
recommended to first use oral nutrition including food adjustment according to patient 503 
preferences, food fortification of meals and providing patients with between-meal 504 
snacks. Also, oral nutritional supplements were recommended to meet nutritional 505 
requirements.10,22 Enteral feeding was advised if at least 75% of energy and protein 506 
targets could be reached within 5 days of oral feeding. Intakes were reassessed every 507 
24-48h. Enteral feeding was provided by nasogastric tube or percutaneous endoscopic 508 
gastrostomy (PEG) depending on expected time course of feeding. If the enteral route 509 
failed to achieve the goal of providing at least 75% of energy and protein targets, start of 510 
parenteral nutrition with a minimal oral or enteral feeding was recommended.   511 
 512 
Figure 2. Flow of patients through EFFORT 513 
 514 
Figure 3. Percentage of patients reaching energy (A) and protein (B) requirements during 515 
the first 10 days post-randomization, in both control and intervention groups 516 
 517 
 518 
19 
 
Figure 4. Kaplan–Meier estimates of the cumulative incidence of the primary endpoint (A) 519 
and all-cause mortality (B) 520 
Panel A shows the Kaplan–Meier curves for the time to the first event of the composite primary 521 
endpoint (p log rank 0.035). Panel B shows the Kaplan–Meier curves for the time to death (p log 522 
rank 0.031).  523 
 524 
Figure 5. Odds ratios for adverse outcome (primary outcome) in prespecified subgroups 525 
The only significant interactions between group assignment and subgroup were for chronic 526 
kidney disease. The body-mass index is the weight in kilograms divided by the square of the 527 
height in meters. NRS denotes nutritional risk screening. 528 
529 
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Table 1. Characteristics of the Patients at Trial Entry* 530 
Characteristic Control group 
(N=1013) 
Intervention group 
(N=1015) 
Socio-demographics   
  Age – yrs – mean (SD) 72.8 (±14.1) 72.4 (±14.1) 
  Age group – number (%)   
   < 65 years 178 (17.6%) 177 (17.4%) 
   65-75 years 322 (31.8%) 349 (34.4%) 
   75 years 513 (50.6%) 489 (48.2%) 
  Male sex – number (%) 539 (53.2%) 525 (51.7%) 
Nutritional assessment   
 *Body mass Index (BMI) – kg/m2 24.7 (±5.3) 24.9 (±5.4) 
  Body weight (Kg) – mean (SD) 70.9 (±16.4) 70.9 (±16.4) 
**NRS – total score – number (%)   
 3 points 314 (31.0%) 310 (30.5%) 
 4 points 384 (37.9%) 391 (38.5%) 
 5 points 261 (25.8%) 263 (25.9%) 
 >5 points 54 (5.3%) 51 (5.0%) 
Admission diagnosis – number (%)  
Infection 315 (31.1%) 298 (29.4%) 
Cancer 173 (17.1%) 201 (19.8%) 
Cardiovascular disease 113 (11.2%) 92 (9.1%) 
Failure to thrive 95 (9.4%) 99 (9.8%) 
Lung disease 75 (7.4%) 50 (4.9%) 
Gastrointestinal disease 68 (6.7%) 96 (9.5%) 
Neurological disease 53 (5.2%) 42 (4.1%) 
Renal disease 34 (3.4%) 34 (3.3%) 
***Metabolic disease 32 (3.2%) 30 (3.0%) 
Other 25 (2.5%) 30 (3.0%) 
Coexisting medical condition – number (%)   
Hypertension 552 (54.5%) 557 (54.9%) 
Malignant disease 329 (32.5%) 338 (33.3%) 
Chronic kidney disease 318 (31.4%) 323 (31.8%) 
Coronary heart disease 279 (27.5%) 287 (28.3%) 
Diabetes 213 (21.0%) 215 (21.2%) 
Congestive heart failure 179 (17.7%) 174 (17.1%) 
COPD 156 (15.4%) 147 (14.5%) 
Peripheral arterial disease 106 (10.5%) 80 (7.9%) 
Cerebrovascular disease 87 (8.6%) 75 (7.4%) 
Dementia 36 (3.6%) 39 (3.8%) 
 531 
*There were no significant differences between the groups at baseline, except for admission 532 
diagnosis of gastrointestinal disease and lung disease, and comorbidity of peripheral arterial 533 
disease. 534 
Percentages may not total 100 because of rounding. 535 
*The body-mass index is the weight in kilograms divided by the square of the height in meters. 536 
** Scores on nutritional risk screening range from 0 to 7, with a score of ≥3 identifying patients 537 
at nutritional risk and higher scores indicating higher risk. 538 
COPD denotes chronic obstructive pulmonary disease. 539 
 540 
21 
 
*** Metabolic disease included hypoglycemia, hyperglycemia, ketoacidosis, electrolyte 541 
disturbances including hyponatremia and hypernatremia, hypokalemia and 542 
hyperkalemia among others 543 
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Table 2. Primary and Secondary Endpoints 
  Control group 
(N=1013) 
Intervention group 
(N=1015) 
Odds ratio or Coefficient  
(95% CI), p value 
Outcome     
Primary outcome – number (%)    
Adverse outcome within 30 days 272 (26.9%) 232 (22.9%) 0.79 (0.64 to 0.97), p=0.023 
Single components of primary outcome – number (%)    
All-cause mortality 100 (9.9%) 73 (7.2%) 0.65 (0.47 to 0.91), p=0.011 
Admission to the intensive care unit (ICU) 26 (2.6%) 23 (2.3%) 0.85 (0.48 to 1.51), p=0.575 
Non-elective hospital readmission  91 (9.0%) 89 (8.8%) 0.99 (0.73 to 1.35), p=0.958 
Major complications    
- Any major complication 76 (7.5%) 74 (7.3%) 0.95 (0.68 to 1.34), p=0.788 
- Nosocomial infection 39 (3.8%) 40 (3.9%) 1.01 (0.63 to 1.59), p=0.98 
- Respiratory failure 13 (1.3%) 14 (1.4%) 1.06 (0.49 to 2.28), p=0.889 
- Major cardiovascular event  7 (0.7%) 8 (0.8%) 1.11 (0.40 to 3.11), p=0.841 
- Acute kidney failure  31 (3.1%) 32 (3.2%) 1.01 (0.61 to 1.69), p=0.956 
- Gastrointestinal events 15 (1.5%) 9 (0.9%) 0.57 (0.25 to 1.31), p=0.186 
Decline in functional status of ≥10%*, no./total no. (%)  55/913 (6.0%) 35/942 (3.7%) 0.62 (0.40 to 0.96), p=0.034 
Additional secondary outcomes     
Length of hospital stay     
- Length of stay – days 9.6 (±6.1) 9.5 (±7.0) -0.21 (-0.76 to 0.35), p=0.46 
Activities of daily living*    
- Barthel score – points 85 (±30) 88 (±26) 3.26 (0.93 to 5.60), p=0.006 
Quality of Life**     
- EQ-5D Visual-analogue scale – points 56 (±29) 59 (±26) 0.13 (0.09 to 0.17), p<0.001 
- EQ-5D index  0.73 (±0.34) 0.75 (±0.32) 3.06 (0.53 to 5.59), p=0.018 
Side effects – number (%)     
Side effects from nutritional support 145 (14.3%) 162 (16.0%) 1.16 (0.90 to 1.51), p=0.258 
- Gastointestinal side effects   40 (3.9%) 43 (4.2%) 1.12 (0.68 to 1.83), p=0.664 
- Complications due to enteral feeding or PN 3 (0.3%) 5 (0.5%) 1.63 (0.38 to 6.95), p=0.507 
- Liver or gall bladder dysfunction 7 (0.7%) 4 (0.4%) 0.54 (0.15 to 1.91), p=0.34 
- Severe hyperglycemia 46 (4.5%) 48 (4.7%) 1.06 (0.69 to 1.61), p=0.801 
- Refeeding syndrome 73 (7.2%) 86 (8.5%) 1.21 (0.86 to 1.70), p=0.272 
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All odds ratios were calculated with logistic regression for binary data and linear regression for 
continuous data. Models were adjusted for predefined prognostic factors (initial NRS and 
baseline Barthel index) and study center.  
ICU denotes intensive care unit; PN denotes parenteral nutrition. CI denotes confidence 
interval. EQ-5D denotes European Quality of Life 5 Dimensions.  
Detailed definitions of outcomes are presented in the supplementary material 
*To estimate decline in functional status we used the Barthel index (scores range from 0 to 100, 
with higher scores indicating better functional status) and compared initial scores on admission 
with scores at 30 days; only survivors were included in this analysis 
**To estimate quality of life we used the European Quality of Life 5 Dimensions index (values 
range from -0.205 to 1, with higher scores indicating better quality of life) including the visual-
analogue scale (EQ-5D VAS) (scores range from 0 to 100, with higher scores indicating better 
health status). 
